Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients with BRAF mutations, combinations of BRAF and MEK inhibitors demonstrated respons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Ascierto, Paolo A., Capone, Mariaelena, Grimaldi, Antonio M., Mallardo, Domenico, Simeone, Ester, Madonna, Gabriele, Roder, Heinrich, Meyer, Krista, Asmellash, Senait, Oliveira, Carlos, Roder, Joanna, Grigorieva, Julia
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440152/
https://ncbi.nlm.nih.gov/pubmed/30925943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0569-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados